Deuterated drugs: Where are we now?

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 10, 2014, Pages 1067-1075

  Timmins, Graham S ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

deuteration; metabolism; obviousness; patent

Indexed keywords

DEUTERATED DRUGS; DEUTERIUM; DRUG; UNCLASSIFIED DRUG;

CHIRALITY; DRUG INDUSTRY; DRUG METABOLISM; PATENT; REVIEW; TOXICITY TESTING; DIAGNOSTIC USE; PHARMACOKINETICS;

DEUTERIUM; DRUG INDUSTRY; PATENTS AS TOPIC; PHARMACOKINETICS;

EID: 84907262678     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.943184     Document Type: Review

References (100)

1. Reinhold DF. Processes for asymmetric conversion of 3-fluoro-L-alanine and 2-deutero-3-fluoro-L-alanine to their D-isomers. US3950411; 1976
2. McCarty LP. Compositions and methods for anesthetizing an animal using deuterated analogues of halothane and chloroform. US4069346; 1978
3. Buteau KC. Deuterated drugs: unexpectedly nonobvious. J High Tech L 2009; 10: 22
4. Gant TG. Using deuterium in drug discovery: leaving the label in the drug. J Med Chem 2013; 57 (9): 3595-611
5. Darland GK, Hajdu R, Kropp H, et al. Oxidative and defluorinative metabolism of fludalanine, 2-2H-3-fluoro-D-alanine. Drug Metab Dispos 1986; 14 (6): 668-73
6. Larsen ER, McCarty LP. Deuterated 1,1-difluoro-2,2-dihaloethyl difluoromethyl ethers. US4154971; 1979
7. Larsen ER, McCarty LP. Deuterated 1,1-difluoro-2,2-dihaloethyl difluoromethyl esters. US4188405; 1980
8. Baker MT, Tinker JH. Deuterated sevoflurane as an inhalational anesthetic. US5789450;, 1998
9. Caille G, Foster RT, Lewanczuk R. Enhancement of the efficacy of nifedipine by deuteration. US5846514; 1998
10. Naicker S, Yatscoff RW, Foster RT. Methods of making deuterated cyclosporin analogs. US7538189; 2009
11. Sanderson K. Big interest in heavy drugs. Nature 2009; 458 (7236): 269
12. Katsnelson A. Heavy drugs draw heavy interest from pharma backers. Nat Med 2013; 19 (6): 656
13. Rao T, Zhang C. Cyclopropyl modulators of p2y12 receptor. US20120301458; 2012
14. Dyck LE, Durden DA, Boulton AA. Effects of deuterium substitution on the catabolism of beta-phenylethylamine: an in vivo study. J Neurochem 1986; 46 (2): 399-404
15. Dewar KM, Dyck LE, Durden DA, et al. Effect of deuterium substitution on the penetration of beta-phenylethylhydrazine into the rat brain. Biochem Pharmacol 1988; 37 (13): 2703-4
16. Dyck LE, Boulton AA. Effect of deuterium substitution on the disposition of intraperitoneal tryptamine. Biochem Pharmacol 1986; 35 (17): 2893-6
17. Ando K, Kawamura K. Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents. US6603008; 2003
18. Foster RT. Method of using deuterated calcium channel blockers. US6221335; 2001
19. Gant TG, Sarshar S. Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties. US20070082929; 2007
20. Ito N, Maesawa T, Muto K, et al. Method for deuteration of a heterocyclic ring. US7517990B2; 2009
21. Kushner D, Baker A, Dunstall T. Pharmacological uses and perspectives of heavy water and deuterated compounds. Can J Physiol Pharmacol 1999; 77 (2): 79-88
22. Poyten MC, Josyula KVB, Gao P, et al. Stabilized deuteroborane-tetrahydrofuran complex. US20070197695; 2007
23. Baillie TA. The use of stable isotopes in pharmacological research. Pharmacol Rev 1981; 33 (2): 81-132
24. Browne TR. Stable isotope techniques in early drug development: an economic evaluation. J Clin Pharmacol 1998; 38 (3): 213-20
25. Cherrah Y, Falconnet J, Desage M, et al. Study of deuterium isotope effects on protein binding by gas chromatography/mass spectrometry. Caffeine and deuterated isotopomers. Biol Mass Spectrom 1987; 14 (11): 653-7
26. Gouyette A. Synthesis of deuterium-labelled elliptinium and its use in metabolic studies. Biol Mass Spectrom 1988; 15 (5): 243-7
27. Haskins N. The application of stable isotopes in biomedical research. Biol Mass Spectrom 1982; 9 (7): 269-77
28. Pieniaszek HJ, Mayersohn M, Adams MP, et al. Moricizine bioavailability via simultaneous, dual, stable isotope administration: bioequivalence implications. J Clin Pharmacol 1999; 39 (8): 817-25
29. Tonn G, Mutlib A, Abbott F, et al. Simultaneous analysis of diphenhydramine and a stable isotope analog (2H10) diphenhydramine using capillary gas chromatography with mass selective detection in biological fluids from chronically instrumented pregnant ewest. Biol Mass Spectrom 1993; 22 (11): 633-42
30. Wolen RL. The application of stable isotopes to studies of drug bioavailability and bioequivalence. J Clin Pharmacol 1986; 26 (6): 419-24
31. Tung RD, Morgan AJ, Silverman IR. 4-hydroxybutyric acid analogs. US20130012565; 2013
32. Czarnik AW. Deuterium-enriched bupropion. US8524780; 2013
33. Liu JF, Tung RD. Substituted dioxopiperidinyl phthalimide derivatives. US20130150408; 2013
34. Cederstav AK, Novak BM. Investigations into the chemistry of thermodynamically unstable species. The direct polymerization of vinyl alcohol, the enolic tautomer of acetaldehyde. J Am Chem Soc 1994; 116 (9): 4073-4
35. Braman V, Graham P, Cheng C, et al. A randomized phase I evaluation of CTP-499, a novel deuterium-containing drug candidate for diabetic nephropathy. Clinical Pharmacology in Drug Development 2013; 2 (1): 53-66
36. Sharma R, Strelevitz TJ, Gao H, et al. Deuterium isotope effects on drug pharmacokinetics. I. System-dependent effects of specific deuteration with aldehyde oxidase cleared drugs. Drug Metab Dispos 2012; 40 (3): 625-34
37. Manley PW, Blasco F, Mestan J, et al. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588. Bioorg Med Chem 2013; 21 (11): 3231-9
38. Jones AD, Paul BJ. Method of utilizing recycled deuterium oxide in the synthesis of deuterated compounds. US20140046060; 2014
39. Harbeson SL. Substituted triazolophthalazine derivatives. US20140024652; 2014
40. Tung RD. Deuterated benzo[d][1,3]-dioxol derivatives. US20140018390; 2014
41. Tung R, Masse CE. Pyrimidine derivatives. US20140018379; 2014
42. Pandya B, Masse CE, Silverman IR, et al. Derivatives of pyrazole-substituted amino-heteroaryl compounds. US20140005211; 2014
43. Liu JF. Substituted isoindoline-1,3-dione derivatives. US20130345282; 2013
44. Harbeson SL, Tung R, Liu JF. Substituted triazolo-pyridazine derivatives. US20130317033; 2013
45. Tung R. Morphinan compounds. US20130310415; 2013
46. Harbeson SL. Substituted triazolo-pyridazine derivatives. US20130225590; 2013
47. Tung R. Substituted dioxopiperidinyl phthalimide derivaties. WO2010056344; 2010
48. Persichetti RA, Liu JF, Masse CE, et al. Analogues of cilostazol. US20130131021; 2013
49. Harbeson SL, Liu JF, Tung R. N-phenyl-2-pyrimidineamine derivatives. US20130121963; 2013
50. Persichetti RA, Liu JF. Fluorouracil derivatives. US20130109707; 2013
51. Tung R. Novel pyrimidinecarboxamide derivatives. US20130109660; 2013
52. Tung RD. Heterocyclic kinase inhibitors. US20130095100; 2013
53. Czarnik AW. Deuterium-enriched dasatinib. US20090076025; 2009
54. Liu JF, Tung R, Harbeson SL. Pyrazinoisoquinoline compounds. US20130029997; 2013
55. Tung RD, Masse CE. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds. US20120295925; 2012
56. Masse CE, Harbeson SL, Tung RD. Prostacyclin derivatives. US20120270934; 2012
57. Liu JF, Persichetti RA. Analogues of cilostazol. US20120264721; 2012
58. Liu JF. Substituted isoindoline-1,3-dione derivatives. US20120252864; 2012
59. Liu JF, Tung RD, Harbeson SL. Fluorinated diaryl urea derivatives. US20120237474; 2012
60. Tung RD, Liu JF, Harbeson SL. Substituted xanthine derivatives. US20120202830; 2012
61. Armstrong R, Watson J, Yeadon M. Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases. US20050107420; 2005
62. Liu JF, Tung R, Harbeson SL. Pyrazinoisoquinoline compounds. US20120149709; 2012
63. Liu JF, Persichetti RA. Deuterated fingolimod. US20120141513; 2012
64. Gant TG, Zhang C, Shahbaz M. Benzoquinolone inhibitors of vmat2. US20120003330; 2012
65. Rao T, Zhang C. Benzazepine inhibitors of gamma-secretase. US20110306596; 2011
66. Rao T, Zhang C. Pyrimidinone inhibitors of lipoprotein-associated phospholipase a2. US20110306552; 2011
67. Rao T, Zhang C. 3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor. US20110257260; 2011
68. Zhang C. Piperidine modulators of dopamine receptor. US20110206782; 2011
69. Gant TG, Sarshar S, Zhang C. Morphinan modulators of nmda receptors, sigma1 receptors, sigma2 receptors, and/or a3b4 nicotinic receptors. US20110206780; 2011
70. Tung R. Morphinan compounds. US20080280936; 2008
71. Zhang C, Sommer A. Trimethoxyphenyl inhibitors of tyrosine kinase. US20110206661; 2011
72. Rao T, Zhang C. 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase. US20110201626; 2011
73. Zhang C. Quinoline inhibitors of tyrosine kinase. US20110195066; 2011
74. Czarnik AW. Deuterium-enriched bupropion. US20140018436; 2014
75. Czarnik AW. Deuterium-enriched lenalidomide. US20130245067; 2013
76. Czarnik AW. Deuterium-enriched donepezil. US20130090357; 2013
77. DeWitt S. 3-deutero-pomalidomide. US20120302605; 2012
78. DeWitt S. 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds. US20120252844; 2012
79. Czarnik AW. Deuterium-enriched ruboxistaurin. US20120136037; 2012
80. Czarnik AW. Deuterium-enriched meropenem. US20120122833; 2012
81. Czarnik AW. Deuterium-enriched ixabepilone. US20120035227; 2012
82. Czarnik AW. Deuterium-enriched dasatinib. US20120015956; 2012
83. Czarnik AW. Deuterium-enriched alogliptin. US20110312983; 2011
84. Czarnik AW. Deuterium-enriched tolterodine. US20110281952; 2011
85. Czarnik AW. Deuterium-enriched doripenem. US20110281927; 2011
86. Czarnik AW. Deuterium-enriched risperidone. US20110212976; 2011
87. Czarnik AW. Deuterium-enriched dapoxetine. US20110201690; 2011
88. Lowe J. Benzophenones and sulfones as inhibitors of glycine uptake. US20020052401; 2002
89. Eggenweiler HM, Wolf M. Pyridazine derivatives. US20050176714; 2005
90. Eatherton A. Pyrimidine derivatives and their use as CB2 modulators. US20060293354; 2006
91. Gu J, Ruppen M. 41-Methoxy isotope labeled rapamycin 42-ester. US20070105888; 2007
92. McCarthy C, Press NJ. Organic compounds. US20090023769; 2009
93. Grahames C, Mallinder P, McIntosh F, et al. Assays for allosteric modulators of G-protein coupled receptors (GPCRs). US20090305321; 2009
94. Castanedo GM, Gunzner JL, Malesky K, et al. Thiazolopyrimidine p13k inhibitor compounds and methods of use. US20090118275; 2009
95. Vasudevan A, Brown BS, Keddy RG, et al. Compounds useful as inhibitors of protein kinases. US20100035919; 2010
96. Pracitto R, Kadow JF, Bender JA, et al. Compounds for the treatment of hepatitis C. US20100184800; 2010
97. Putnam AMAH, Knudsen N, Norman T, et al. Modified bovine G-CSF polypeptides and their uses. US20100035812; 2010
98. Follmann M, Stasch JP, Redlich G, et al. Substituted 5-fluoro-1H-pyrazolopyridines and their use. US20120022084; 2012
99. Babin D, Bedel O, Gouyon T, et al. 9h-pyrrolo[2,3-b: 5,4-c] dipyridine azacarboline derivatives, preparation thereof, and therapeutic use thereof. US20120208809; 2012
100. Gong Y, Zinser HB. Process for the preparation of sulfamide derivatives. US20130085176; 2013